Get started

Pharmaceuticals

ERIS Lifesciences for 25% gainsDate: 3 Dec’24 Symbol: ERIS Timeframe: Weekly ERIS Lifesciences currently seems to be in Wave V of 3 which is heading towards 1960-70 (25% from current price of 1470) as seen in the chart. Wave 4 could then correct back to 1300 levels. The company, in the recently announced September quarter results has posted best ever revenues and operating profits. This is not a prediction but a possible wave count. This is also not a recommendation to trade or invest. Please do your own analysis. HINGLISH VERSION ERIS Lifesciences vartamaan mein Wave 3 ki V mein dikh rahee hai jo 1960-70 (vartamaan keemat 1470 se 25%) kee taraf badh rahee hai jaisa ki chart mein dekh sakte hain. Wave 4 phir 1300 ke star tak neeche aa sakta hai. Company ne haal hee mein ghoshit September quarter results mein ab tak ka sabse achchha revenue aur operating profit darj kiya hai. Yah koi prediction nahin balki sambhaavit Wave count hai. Yah trade lene ya invest karne ki bhi salaah nahi hai. Kripya apana vishleshan khud karein.
NSE:ERISLong
by DhandhaPaani
Jubilant Ingrevia for 60%+ gainsDate: 3 Oct’24 Stock: Jublingrea Timeframe: Daily chart Jubilant Ingrevia seems to be in Wave III of 3 which is heading towards 1300+ (60%+ from current price of 810) as seen in the chart. Wave III could end around 940 and Wave IV could correct to 750 levels (returns would be even higher if entered at the end of Wave IV of 3). High volume and strong RSI support this stance. If the industry tailwinds remain, it won’t surprise me if the target is done in a year’s time. This is not a trade recommendation. Please do your own analysis. Jubilant Ingrevia 3 ke Wave III mein dikh raha hai jo 1300+ (800 ki vartamaan keemat se 60%+) kee taraf badh raha hai jaisa ki chart mein dikh raha hai. Wave III 940 ke aas-paas samaapt ho sakta hai aur Wave IV 750 ke star tak neeche aa sakta hai (yadi 3 ke Wave IV ke ant mein entry ki jaye to return aur bhee adhik hoga). Adhik volume aur majaboot RSI is trend ka samarthan karate hain. Yadi sector mein teji kee sthiti banee rahee, to yah koee aascharya kee baat nahin hogee yadi lakshya ek varsh ke bheetar poora ho jae. Yeh koi invest karne ki hitaayad nahin hai. Kripya apana analysis khud karein.
NSE:JUBLINGREALong
by DhandhaPaani
2
Neat and Clean Breakout seen in Pharmaceuticals companyHello Everyone, i hope you all will be doing good. I have brought an analysis on Pharmaceuticals stock which has given neat and clean short term consolidation zone breakout. Stock name is Alembic Pharmaceuticals and it is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. Leading Pharma company:- The company has 3 R&D and 5 manufacturing facilities. Alembic is among the top 25 players in domestic formulations market. The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulation brands in India. It has a share of 1.5% in the domestic market. Market Share:- The company has 1.5% share of the Indian Pharma market with 4 brands with revenue of Rs.1 bn. Its products like Roxid has ~95% market share, Althrocin (~90%), Deltone (~67%), Gerijoint (~50%), Elata (~50%) etc. Prescription wise Alembic ranks at 18th Position. Technically stock has given breakout of short term consolidation breakout of Rectangle pattern with good volume, there is higher probability that we can see this stock towards 1500+ in short term and 2500+ in long term. Stock is above 200-DEMA, and MACD Indicator is showing bullish crossover. Volume indicator is suggesting huge bullishness in coming few months. Market Cap ₹ 21,237 Cr. Current Price ₹ 1,080 High / Low ₹ 1,119 / 682 Stock P/E 34.6 Book Value ₹ 245 Dividend Yield 1.02 % ROCE 13.1 % ROE 13.3 % Face Value ₹ 2.00 Industry PE 34.6 Debt ₹ 513 Cr. EPS ₹ 31.3 Promoter holding 69.6 % Intrinsic Value ₹ 490 Pledged percentage 0.00 % EVEBITDA 22.6 Change in Prom Hold 0.00 % Profit Var 5Yrs 1.07 % Sales growth 5Years 9.62 % Return over 5years 16.0 % Debt to equity 0.11 Net profit ₹ 616 Cr. ROE 5Yr 15.9 % Profit growth 77.2 % Earnings yield 3.17 % Disclaimer:- Please always do your own analysis or consult with your financial advisor before taking any kind of trades. Dear traders, If you like my work then do not forget to hit like and follow me, and guy's let me know what do you think about this idea in comment box, i would be love to reply all of you guy's. Thankyou.
NSE:APLLTDLong
by TraderRahulPal
AARTI DRUGS - Price Observation & OverviewPrice Observation & Overview: 1. Currently reacting from the supply zone and trendline. 2. Volumes are dry! 3. Earnings are weak. 4. Buying strength is lacking at the moment. Plan: 1. Wait and observer. 2. Will try to update a follow-up review post in the next week if found anything interesting and significant... - Stay tuned for further insights, updates and trade safely! - If you liked the analysis, don't forget to leave a comment and boost the post. Happy trading! Disclaimer: This is NOT a buy/sell recommendation. This post is meant for learning purposes only. Please, do your due diligence before investing. Thanks & Regards, Anubrata Ray
NSE:AARTIDRUGS
by SuperNova396
Small Rectangle pattern Breakout || Positional Trade in IPCA LABHello Guy's i have brought an idea which can be best positional trade as this stock has given breakout, i have done my analysis on daily time frame, Breakout is sustaining above the previous highs, Stock has made fresh all time high in today's session. Stock is good with good liquidity.. MACD also has given bullish crossover Price and action suggesting a move at least for 8-10% in short term. Disclaimer:- Please always do your own analysis or consult with your financial advisor before taking any kind of trades. Dear traders, If you like my work then do not forget to hit like and follow me, and guy's let me know what do you think about this idea in comment box, i would be love to reply all of you guy's. Thankyou.
NSE:IPCALABLong
by TraderRahulPal
9
INDSWFT LAB :- A STRONG BREAKOUT ON THE LINE NSE:INDSWFTLAB Ind-Swift Laboratories Ltd. engages in the manufacture, development, and marketing of pharmaceutical ingredients. The firm operates throughout India and Outside India's geographical segments. Its products include API's and impurities. The firm supplies active pharmaceutical ingredients to pharmaceutical companies and also provides research and development services. 📊Technical analysis: 1. IT has formed a strong horizontal resistance at 125 zone from the last 13 years. 2. Now it's consolidating near resistance for a few weeks and may attempt to break that. 3. Volume has been spiking. 4. Trading above all EMA clusters (short, mid and long term EMA) 🟢Entry : Wait for a day candle confirmation to close it above the 125 level then enter the high. 🔴Same with stop-loss levels it will be triggered on weekly candle closing. ⏳Trade Duration: Few months ( positional basis) 🎯Targets are marked on the chart. Finally reached here then like please share with friends. Keep Learning, Happy Trading.
NSE:INDSWFTLABLong
by SANJAYPATIDAR_
Granules India: Breakout Confirmed, Long Opportunity EmergesAnalysis: The chart of Granules India on TradingView suggests a promising breakout opportunity, potentially signaling a long entry chance for traders. Let's analyze the details based on the information provided on chart. Current Price: ₹455.75, above the old year resistance level of ₹436.20 marked by the orange line. Breakout Confirmation: The recent surge past the resistance zone, accompanied by strong volume, confirms a potential trend reversal from resistance to support. Uptrend Momentum: The sustained price increase after the breakout indicates continuing buying pressure, hinting at further upside potential. Trading Strategies: Aggressive: Enter long if the price closes and sustains above the current level (₹455.75) with continued buying volume. Implement a stop-loss order below the breakout level (₹436.20) to manage risk. Potential target prices could be ₹480 and ₹505 based on chart patterns and Fibonacci extensions Conservative: Wait for a potential pullback towards the breakout level (₹436.20) or within the previous consolidation zone (₹410-₹430) (highlighted in the image). Enter long if the price finds support at the pullback zone and exhibits bullish reversal signs (e.g., hammer candlestick pattern). Utilize a stop-loss order below the pullback low for effective risk management. Additional Considerations: The stock market is volatile, and breakouts can sometimes fail. Conduct your own fundamental research to assess Granules India's financial health, industry outlook, and future prospects before making investment decisions. Manage your risk effectively using stop-loss orders and appropriate position sizing. Disclaimer: This analysis is for educational purposes only and should not be considered financial advice. Please do your own research before making any investment decisions.
NSE:GRANULESLong
by TRADING-NASA
Natco Pharma: Sustained Breakout or Pullback Retest?Analysis: The chart of Natco Pharma Ltd. on TradingView depicts an intriguing post-breakout scenario, presenting both potential long entry and cautious approaches for traders. Let's dissect the situation: Current Price : ₹1026.50, well above the multi-year resistance level of ₹921.10 marked by the orange line. Breakout Confirmation: The recent surge past the resistance zone, accompanied by strong volume, confirms a potential trend reversal from resistance to support. Uptrend Momentum: The sustained price increase after the breakout indicates continued buying pressure, suggesting further upside potential. However, a crucial question arises: Has the breakout momentum exhausted, or is a pullback retest imminent? Aggressive: Option 1 (Immediate Long): Enter long if the price closes and sustains above the current level (₹1026.50) with persistent buying volume. This aggressive approach assumes the uptrend will continue. Option 2 (Breakout Confirmation): Enter long only if the price retests and decisively breaks above the breakout level (₹921.10) with renewed buying volume. This option waits for confirmation before committing. Conservative: Wait for Pullback: Wait for a potential pullback towards the breakout level (₹921.10) or within the previous consolidation zone (₹850-₹920). Enter long only if the price finds support at the pullback zone and exhibits bullish reversal signs (e.g., hammer candlestick pattern). This approach prioritizes minimizing risk by waiting for confirmation. Additional Considerations: The stock market is inherently volatile, and even confirmed breakouts can experience pullbacks. Conduct thorough fundamental research to assess Natco Pharma's financial health, industry outlook, and future prospects before making investment decisions. Implement prudent risk management through stop-loss orders and appropriate position sizing. Disclaimer: This analysis is for educational purposes only and should not be considered financial advice. Please conduct your own research before making any investment decisions.
NSE:NATCOPHARMLong
by TRADING-NASA
SMS Pharmaceuticals: Long Opportunity After Multi-Year BreakoutAnalysis: The provided chart of SMS Pharmaceuticals (SMS Pharma) on TradingView reveals a potentially lucrative breakout opportunity. Let's break it down: Current Price: ₹145.45, comfortably above the multi-year resistance level of ₹136 marked by the blue line. Breakout Confirmation: The recent surge past the resistance zone, accompanied by strong volume, suggests a potential trend reversal from resistance to support. Uptrend Momentum: The sustained price increase after the breakout indicates continued buying pressure, hinting at further upside potential. Trading Strategies: Aggressive: Enter long if the price closes and sustains above the current level (₹145.45) with persistent buying volume. Implement a stop-loss order below the breakout level (₹130 ) to manage risk. Potential target prices could be ₹160 and ₹175 based on chart patterns and Fibonacci extensions. Conservative: Wait for a potential pullback towards the breakout level (₹136) or within the previous consolidation zone (₹120-₹136). Enter long if the price finds support at the pullback zone and exhibits bullish reversal signs (e.g., hammer candlestick pattern). Utilize a stop-loss order below the pullback low for effective risk management Additional Considerations: While technical analysis is insightful, remember that the stock market remains inherently volatile. Conduct thorough fundamental research to assess SMS Pharma's financial health, industry outlook, and future prospects before making investment decisions. Implement prudent risk management through stop-loss orders and appropriate position sizing. Disclaimer: This analysis is for educational purposes only and should not be considered financial advice. Please conduct your own research before making any investment decisions.
NSE:SMSPHARMALong
by TRADING-NASA
Laurus Labs Ltd | Pharma multibagger momentum stockLaurus Labs Ltd | Pharma multibagger momentum stock Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) Financial: excellent Market Cap = 23,185 Cr. ROCE = 22.2 % ROE = 20.4 % Debt to equity = 0.45 Promoter holding = 27.2 % Piotroski score = 5.00 Quick ratio = 0.64 Current ratio = 1.31 Profit Var 3Yrs = 41.6 % Sales growth 3Years = 27.3 % Return on assets = 11.2 % in sector rotation now its pharma time to move up. big player heavily buying in pharma sector. this stock is big one momentum stock. since long consolidation RSI up move in momentum zone. we have to ready for participate and grab the opportunity . moreover financially also stable pharma company. Note: I am not SEBI registered financial Adviser. I solely present my views on chart .I do not charge any kind of service. This is not buy sell recommendation. If you like my ideas than like boost and follow me for more ideas. Thanks and comment freely
NSE:LAURUSLABSLong
by Momentuminvesting5540
Sequent Scientific PE is negative at -42 THE CARLYLE GROUP ACQUIRES A MAJORITY STAKE IN SEQUENT SCIENTIFIC LIMITED Shares of Sequent Scientific soared over 9 percent in early trade on September 15 after the company's board approved the sale of its API (Active Pharmaceutical Ingredient) facility in Thane Sequent Scientific (NSE:SEQUENT) delivers shareholders decent 8.8% CAGR over 5 years Sequent Scientific shares jump 15% after terminating Tineta Pharma's proposed acquisition mutual funds have increased stake from 0.25% to 1% DII also increasing stake significantly stock has come out of accumulation Phase!!!
NSE:SEQUENTLong
by rsptraders2017